

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5798690

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ATXCO, INC.		10/28/2019
RECEIVING PARTY DATA		
Name:	SABRE THERAPEUTICS LLC	
Street Address:	442 LITTLEFIELD AVENUE	
City:	SOUTH SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94080	
PROPERTY NUMBERS Total: 22		
Property Type	Number	
Application Number:	61883026	
Application Number:	62038052	
Application Number:	15023465	
Application Number:	61878922	
Application Number:	15022167	
Application Number:	61907947	
Application Number:	62038093	
Application Number:	15036370	
Application Number:	15892142	
Application Number:	61878945	
Application Number:	15022180	
Application Number:	61907965	
Application Number:	62038121	
Application Number:	14926877	
Application Number:	15060398	
Application Number:	15261659	
Application Number:	15970337	
Application Number:	14462459	
Application Number:	62131744	
Application Number:	62131721	

PATENT

Property Type	Number
Application Number:	62167216
Application Number:	15574769

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8583502300

Email: qwolfe@wsgr.com, patentdocket@wsgr.com, lmiller@wsgr.com

Correspondent Name: WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94306

ATTORNEY DOCKET NUMBER:	57502-700
NAME OF SUBMITTER:	QUINN WOLFE
SIGNATURE:	/QUINN WOLFE/
DATE SIGNED:	10/31/2019

Total Attachments: 6

source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page1.tif
source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page2.tif
source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page3.tif
source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page4.tif
source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page5.tif
source=57502 Corporate to Corporate IP Assignment_Oct 28 2019_Notarized#page6.tif

WHEREAS, ATXCO, INC. (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Applications set forth in Schedule A (hereinafter "Applications") The term "Applications" also includes all patent applications that share or claim priority to or from the applications set forth in Schedule A and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions").

WHEREAS, SABRE THERAPEUTICS, LLC a limited liability company of the State of Delaware, having a place of business at 442 Littlefield Avenue, South San Francisco, CA 94080 (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number: 57502

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

ASSIGNOR: ATXCO, Inc.

Date: Oct. 28, 2019By: [Signature]Name: FELIX KARIM
Title: EVP

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California _____)

County of San Mateo _____)On Oct 28, 2019 before me, Matt G. Miller, Notary Public


Date

Here Insert Name and Title of the Officer

personally appeared Felix Karim

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: [Signature]
Signature of Notary Public

Place Notary Seal Above

RECEIVED AND AGREED TO BY ASSIGNEE:

SABRE THERAPEUTICS LLC

Date: October 26, 2019By: [Signature]Name: WENDIE ROBBINS
Title: CEO

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California _____)

County of San Mateo _____)On Oct 28, 2019 before me, Matt G. Miller, Notary Public

Date

Here Insert Name and Title of the Officer

personally appeared Wendie Rae Robbins

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: [Signature]
Signature of Notary Public

Place Notary Seal Above

SCHEDULE A

WSGR Ref.	Country	Appl. Number	Filing Date	Patent No.
57502-709.101	U.S.	61/883,026	26-Sep-2013	
57502-709.601	PCT	PCT/US2014/057477	25-Sep-2014	
57502-709.102	U.S.	62/038,052	15-Aug-2014	
57502-709.831	U.S.	15/023,465	21-Mar-2016	9,850,203
57502-709.761	JP	2016-517562	25-Sep-2014	
57502-709.611	EP	14848029.6	25-Sep-2014	
57502-710.101	US	61/878,922	17-Sep-2013	
57502-710.601	WO	PCT/US2014/055901	16-Sep-2014	
57502-710.761	JP	2016-515446	16-Sep-2014	
57502-710.611	EP	14846301.1	16-Sep-2014	
57502-710.831	US	15/022,167	15-Mar-2016	9,714,240
57502-711.891	HK	16114542.6	21-Dec-2016	
57502-711.101	US	61/907,947	22-Nov-2013	
57502-711.102	US	62/038,093	15-Aug-2014	
57502-711.601	WO	PCT/US2014/066705	20-Nov-2014	
57502-711.681	AU	2014352887	20-Nov-2014	
57502-711.691	BR	11 2016 010221 5	20-Nov-2014	
57502-711.701	CA	2,930,735	20-Nov-2014	
57502-711.711	CN	201480063882.4	20-Nov-2014	CN105764903
57502-711.591	EA	201690880	20-Nov-2014	
57502-711.611	EP	14863158.3	20-Nov-2014	
57502-711.731	IL	245389	20-Nov-2014	
57502-711.741	IN	201617014688	20-Nov-2014	
57502-711.761	JP	2016-533529	20-Nov-2014	
57502-711.771	KR	10-2016-7014492	20-Nov-2014	

WSGR Ref.	Country	Appl. Number	Filing Date	Patent No.
57502-711.781	MX	MX/a/2016/006688	20-Nov-2014	
57502-711.801	PH	1-2016-500863	20-Nov-2014	
57502-711.821	SG	11201603917Y	20-Nov-2014	
57502-711.841	ZA	2016/03030	20-Nov-2014	
57502-711.831	US	15/036,370	12-May-2016	9,926,318
57502-711.791	NZ	720473	20-Nov-2014	
57502-711.911	MY	PI 2016000960	20-Nov-2014	
57502-711.861	TH	1601002940	20-Nov-2014	
57502-711.581	VN	1-2016-01883	20-Nov-2014	
57502-711.881	CL	201601232	20-Nov-2014	
57502-711.9631	CO	16-158,947	20-Nov-2014	33438
57502-711.721	CR	2016-0290	20-Nov-2014	
57502-711.271	NI	2016-000070	20-Nov-2014	
57502-711.951	PE	000667-2016	20-Nov-2014	
57502-711.301	US	15/892,142	08-Feb-2018	
57502-712.101	US	61/878,945	17-Sep-2013	
57502-712.601	WO	PCT/US2014/055899	16-Sep-2014	
57502-712.761	JP	2016-515449	16-Sep-2014	
57502-712.611	EP	14845959.7	16-Sep-2014	
57502-712.831	US	15/022,180	15-Mar-2016	9,951,026
57502-713.891	HK	16114544.4	21-Dec-2016	
57502-713.101	US	61/907,965	22-Nov-2013	
57502-713.102	US	62/038,121	15-Aug-2014	
57502-713.301	US	14/926,877	29-Oct-2015	9,334,261
57502-713.601	WO	PCT/US2014/066706	20-Nov-2014	
57502-713.401	US	15/060,398	03-Mar-2016	9,468,628
57502-713.681	AU	2014352888	20-Nov-2014	

WSGR Ref.	Country	Appl. Number	Filing Date	Patent No.
57502-713.6811	AU	2019213425	20-Nov-2014	
57502-713.691	BR	11 2016 010220 7	20-Nov-2014	
57502-713.701	CA	2,930,737	20-Nov-2014	
57502-713.711	CN	201480063881.X	20-Nov-2014	
57502-713.591	EA	201690881	20-Nov-2014	030068
57502-713.611	EP	14864293.7	20-Nov-2014	
57502-713.731	IL	245383	20-Nov-2014	
57502-713.741	IN	201617014884	20-Nov-2014	
57502-713.761	JP	2016-533532	20-Nov-2014	6501367
57502-713.771	KR	10-2016-7014496	20-Nov-2014	
57502-713.781	MX	MX/a/2016006623	20-Nov-2014	
57502-713.801	PH	1-2016-500862	20-Nov-2014	
57502-713.821	SG	11201603816V	20-Nov-2014	11201603816V
57502-713.841	ZA	2016/03083	20-Nov-2014	
57502-713.911	MY	P1 2016000959	20-Nov-2014	
57502-713.861	TH	1601002941	20-Nov-2014	
57502-713.581	VN	1-2016-01882	20-Nov-2014	
57502-713.791	NZ	720478	20-Nov-2014	
57502-713.881	CL	201601231	20-Nov-2014	
57502-713.9631	CO	16-158,919	20-Nov-2014	34533
57502-713.721	CR	2016-0289	20-Nov-2014	
57502-713.7211	CR	2019-394	20-Nov-2014	
57502-713.271	NI	2016-000071	20-Nov-2014	
57502-713.951	PE	669-2016	20-Nov-2014	
57502-713.302	US	15/261,659	09-Sep-2016	9,999,615
57502-713.303	US	15/970,337	03-May-2018	
57502-713.7111	CN	201910686732.3	20-Nov-2014	

WSGR Ref.	Country	Appl. Number	Filing Date	Patent No.
57502-717.601	WO	PCT/US2015/045518	17-Aug-2015	
57502-717.201	US	14/462,459	18-Aug-2014	9,051,320
57502-717.761	JP	2017-508482	17-Aug-2015	
57502-717.611	EP	15833802.0	17-Aug-2015	
57502-722.101	US	62/131,744	11-Mar-2015	
57502-722.601	WO	PCT/US2016/020733	03-Mar-2016	
57502-723.101	US	62/131,721	11-Mar-2015	
57502-723.601	WO	PCT/US2016/020737	03-Mar-2016	
57502-724.101	US	62/167,216	27-May-2015	
57502-724.601	WO	PCT/US2016/033933	24-May-2016	
57502-724.681	AU	2016268250	24-May-2016	
57502-724.691	BR	11 2017 025420 4	24-May-2016	
57502-724.701	CA	2,986,759	24-May-2016	
57502-724.711	CN	201680044106.9	24-May-2016	
57502-724.591	EA	201792604	24-May-2016	
57502-724.611	EP	16800640.1	24-May-2016	
57502-724.731	IL	255764	24-May-2016	
57502-724.761	JP	2017-560309	24-May-2016	
57502-724.771	KR	10-2017-7036376	24-May-2016	
57502-724.781	MX	MX/a/2017/015225	24-May-2016	
57502-724.821	SG	11201709570U	24-May-2016	
57502-724.831	US	15/574,769	16-Nov-2017	
57502-724.891	HK	18112793.4	24-May-2016	